pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$EXELEXELIXIS, INC.

$EXEL53.69-1.29%
Alameda, CA, USupdated 9h ago

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
8
marketed
1
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(8)

pipeline depth8 products
Phase 1: 4Phase 3: 1Marketed: 1pre_registration: 1Unknown: 1
4Phase 11Phase 31Marketed1pre_registration1Unknown
Marketed
cabozantinib s-malate
Endometrial Cancer
Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2
Phase 3
CABOMETYX
1 INDICATIONS AND USAGE CABOMETYX is a kinase inhibitor i…
Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2
Phase 1
XB-010
Endometrial Cancer
Phase 1
XB-371
Solid Tumor
Phase 1
XB-628
Solid Tumor
Phase 1
XL-309
Fallopian Tube Cancer
drug
COMETRIQ
1 INDICATIONS AND USAGE COMETRIQ is indicated for the tre…
Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2
pre_registration
zanzalintinib fumarate
Metastatic Colorectal Cancer

📅 Upcoming

Oct 27, 2026
earnings
$EXEL53.69-1.29%
in 2mo
EXELIXIS, INC. earnings
EXELIXIS, INC.
→

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Feb 24, 26SELLAftab Dana· EVP, Research and Development47,918 sh @ $44.50−$2.13M↗
routine RSU / option mechanics (6)
  • Feb 26, 26grantSenner Christopher J. · EVP and CFO52,018 sh
  • Feb 26, 26grantHefti Brenda · SVP and General Counsel23,119 sh
  • Feb 26, 26grantAftab Dana · EVP, Research and Development52,018 sh
  • Feb 26, 26grantMORRISSEY MICHAEL · President and CEO160,437 sh
  • Feb 26, 26grantHaley Patrick J. · EVP, Commercial40,459 sh
  • Feb 24, 26giftMORRISSEY MICHAEL · President and CEO100,278 sh
🐶 Hiring Signal
next earnings Oct 27, 2026
No open roles indexed yet — view EXELIXIS, INC. jobs →

News

  • Out of sight, out of work? What’s driving remote job cuts
    Biopharma professionals sometimes find themselves out of jobs when employers want to bring staff back into the office, as recently seen at biotech EMD Serono and Exelixis.
    biospace · 1d ago
identifiers
ticker
$EXEL
SEC CIK
0000939767
country
US
source
sec_tickers
top tags
Oncology6NSCLC2
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 39m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?